Mundipharma Partners With Samsung Bioepis For Hong Kong And Taiwan
Partnership Covers Adalimumab, Etanercept, Trastuzumab and Bevacizumab
Executive Summary
Mundipharma and Samsung Bioepis are undertaking an exclusive commercialization partnership for a portfolio of biosimilars in Hong Kong and Taiwan.